Journal
JOURNAL OF CARDIOVASCULAR TRANSLATIONAL RESEARCH
Volume 11, Issue 6, Pages 439-449Publisher
SPRINGER
DOI: 10.1007/s12265-018-9797-x
Keywords
Physiological cardiac hypertrophy; Pathological cardiac hypertrophy; MicroRNAs (miRNAs); Long noncoding RNAs (lncRNAs); Circular RNAs (circRNAs)
Funding
- CAMS Innovation Fund for Medical Sciences (CIFMS) [2016-12M-1-006]
- National Natural Science Foundation of China [81400647]
Ask authors/readers for more resources
Cardiac hypertrophy is classified as pathological and physiological hypertrophy. Pathological hypertrophy typically precedes the onset of heart failure, one of the largest contributors to disease burden and deaths worldwide. In contrast, physiological hypertrophy is an adaptive response and protects against adverse cardiac remodeling. Noncoding RNAs (ncRNAs) have drawn significant attention over the last couple of decades, and their dysregulation is increasingly being linked to cardiac hypertrophy and cardiovascular diseases. In this review, we will summarize the profiling, function, and molecular mechanism of microRNAs, long noncoding RNAs, and circular RNAs in pathological cardiac hypertrophy. Additionally, we also review microRNAs responsible for physiological hypertrophy. With better understanding of ncRNAs in cardiac hypertrophy, manipulation of the important ncRNAs will offer exciting avenues for the prevention and therapy of heart failure.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available